Evolus to Participate in 2025 Stifel Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a leading performance beauty company, has announced its participation in the upcoming Stifel Healthcare Conference on November 11, 2025. Members of Evolus's management team will engage in a fireside chat and conduct investor meetings at the event, scheduled for 11:20 AM ET. Investors and interested parties can access the fireside chat via the Investor Relations page on the Evolus website, with a replay available for 90 days following the presentation.

Evolus is committed to redefining the aesthetic injectable market for a new generation of beauty consumers through its innovative, customer-centric model. The company focuses on delivering outstanding products and services in the beauty sector. Among its flagship offerings, Jeuveau ® (prabotulinumtoxinA-xvfs) stands out as the first neurotoxin exclusively dedicated to aesthetic applications. Additionally, the company boasts a unique collection of injectable hyaluronic acid (HA) gels under the brand name Evolysse ™, further solidifying its presence in the marketplace.

Evolus aims to become a global leader in aesthetics by leveraging its innovative digital platform and developing a comprehensive portfolio of consumer brands that resonate with today's beauty enthusiasts.

For more information, Evolus encourages interested parties to visit their official website or follow them on social media platforms such as LinkedIn, X, Instagram, and Facebook. The company has made investments in communication with investors and media, led by Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications.

Overall, Evolus’s participation in the Stifel Healthcare Conference exemplifies its commitment to transparency and engagement with the investment community as it continues to expand its footprint in the aesthetics market.

Evolus, Inc. (NASDAQ: EOLS) is poised to make significant waves in the aesthetics sector with its upcoming participation in the 2025 Stifel Healthcare Conference on November 11. Attending this high-profile event signals its commitment to engaging investors and showcasing its innovative product offerings, such as Jeuveau® and Evolysse™.

Evolus is redefining the performance beauty market, focusing on aesthetics, which is rapidly growing due to increasing consumer demand for non-invasive treatments. The unique customer-centric strategy of moving towards a digital platform positions Evolus advantageously against competitors. Investors should note that the company's strong emphasis on innovation, particularly with Jeuveau® being the only neurotoxin dedicated exclusively to aesthetics, highlights its intent to capture a significant share of the injectable market.

The upcoming fireside chat represents an opportunity for investors to gain insights into the company's strategies, plans for growth, and product pipeline. This session may provide valuable information that could influence investor sentiment and stock performance, especially in the wake of the burgeoning demand for aesthetic procedures.

Evolus's focus on establishing a robust aesthetic portfolio is essential as consumer trends lean towards personalized and effective beauty solutions. The anticipated discussions around market dynamics, product differentiation, and investment in R&D could provide traction for further stock appreciation, particularly if the management outlines solid growth prospects in their investor meetings.

In summary, Evolus's proactive approach and innovative solutions in the aesthetic market warrant close attention. Long-term investors may find an opportunity at this juncture to gain exposure to a rapidly growing segment within healthcare. Monitoring the dialogue at the Stifel Healthcare Conference will be crucial for gauging future investor confidence and market traction.